公开(公告)号：US20240285617A1

公开(公告)日：2024-08-29

申请号：US18591753

申请日：2024-02-29

Applicant: Jacobio Pharmaceuticals Co., Ltd.

Inventor： Huifeng Han ,  Panliang Gao ,  Cunbo Ma ,  Di Kang

IPC: A61K31/497 ,  A61K31/438 ,  A61K31/444 ,  A61K31/4545 ,  A61K31/4985 ,  A61K31/501 ,  A61K31/506 ,  A61K31/513 ,  A61K31/519 ,  A61K31/53 ,  A61K31/5377 ,  C07D401/04 ,  C07D401/14 ,  C07D405/14 ,  C07D417/04 ,  C07D471/10 ,  C07D487/04 ,  C07D491/107 ,  C07D495/10 ,  C07D513/04 ,  C07D513/10 ,  C07D519/00

CPC classification number: A61K31/497 ,  A61K31/438 ,  A61K31/444 ,  A61K31/4545 ,  A61K31/4985 ,  A61K31/501 ,  A61K31/506 ,  A61K31/513 ,  A61K31/519 ,  A61K31/53 ,  A61K31/5377 ,  C07D401/04 ,  C07D401/14 ,  C07D405/14 ,  C07D417/04 ,  C07D471/10 ,  C07D487/04 ,  C07D491/107 ,  C07D495/10 ,  C07D513/04 ,  C07D513/10 ,  C07D519/00 ,  C07B2200/05

Abstract: This invention provides a compound of formula I, their synthesis and their use for treating a SHP2 mediated disorder. More particularly, this invention provides a pharmaceutical composition comprising the said compound.

公开(公告)号：US20240270759A1

公开(公告)日：2024-08-15

申请号：US18559830

申请日：2022-05-07

Applicant: Ya Therapeutics Inc

Inventor： Yonghong LIANG ,  Zhiyong XU ,  Zhaosen ZENG ,  Wenguang YAN ,  Fangjun XIONG

IPC: C07D519/00 ,  A61K31/495 ,  A61K31/501 ,  A61K31/506 ,  A61K31/517 ,  A61K31/519 ,  A61K31/53 ,  C07D401/04 ,  C07D471/10 ,  C07D475/02 ,  C07D491/107

CPC classification number: C07D519/00 ,  A61K31/495 ,  A61K31/501 ,  A61K31/506 ,  A61K31/517 ,  A61K31/519 ,  A61K31/53 ,  C07D401/04 ,  C07D471/10 ,  C07D475/02 ,  C07D491/107

Abstract: The present invention has disclosed SHP2 phosphatase inhibitors and its applications. Specifically, the present invention has disclosed the compounds shown in the general formula (I), methods of preparation thereof, and pharmaceutical compositions containing the compound, and their use as tyrosine phosphatase SHP-2 inhibitors in the treatment of leukemia, neuroblastoma, melanoma, acute myeloid leukemia, breast cancer, esophageal cancer, lung cancer, colon cancer, head cancer, pancreatic cancer, head and neck squamous cell carcinoma, stomach cancer, liver cancer, anaplastic large cell lymphoma, and glioblastoma, wherein each substituent in general formula (I)k is as defined in the specification.

公开(公告)号：US20240262807A1

公开(公告)日：2024-08-08

申请号：US18561553

申请日：2022-05-27

Applicant: CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD.

Inventor： Yinsheng ZHANG ,  Xin LIU ,  Hui QIN ,  Jiawei YE ,  Jinan WANG ,  Songsong WU

IPC: C07D401/14 ,  A61K31/407 ,  A61K31/4439 ,  A61K31/444 ,  A61K31/501 ,  A61K31/506 ,  A61K31/519 ,  A61K31/5377 ,  A61K31/5383 ,  A61K31/5386 ,  A61K31/541 ,  A61P35/02 ,  C07D213/82 ,  C07D401/04 ,  C07D405/14 ,  C07D413/14 ,  C07D471/04 ,  C07D487/04 ,  C07D491/048 ,  C07D491/107 ,  C07D498/04 ,  C07D498/08 ,  C07D519/00

CPC classification number: C07D401/14 ,  A61K31/407 ,  A61K31/4439 ,  A61K31/444 ,  A61K31/501 ,  A61K31/506 ,  A61K31/519 ,  A61K31/5377 ,  A61K31/5383 ,  A61K31/5386 ,  A61K31/541 ,  A61P35/02 ,  C07D213/82 ,  C07D401/04 ,  C07D405/14 ,  C07D413/14 ,  C07D471/04 ,  C07D487/04 ,  C07D491/048 ,  C07D491/107 ,  C07D498/04 ,  C07D498/08 ,  C07D519/00

Abstract: Provided are a compound used as a BCR-ABL inhibitor, namely a compound of formula (I), or a pharmaceutically acceptable salt thereof, a preparation method therefor, and a pharmaceutical composition comprising the compound. Moreover, the present invention relates to a use of the compound in the preparation of a drug for treating BCR-ABL related diseases.

公开(公告)号：US20240254115A1

公开(公告)日：2024-08-01

申请号：US18557933

申请日：2022-04-29

Applicant: ACONDICIONAMIENTO TARRASENSE

Inventor： Carmen ALMANSA-ROSALES ,  Marina VIRGILI-BERNADÓ ,  Mónica ALONSO-XALMA ,  Ute CHRISTMANN

IPC: C07D413/14 ,  A61K31/4439 ,  A61K31/444 ,  A61K31/4545 ,  A61K31/5377 ,  A61K31/5386 ,  A61K31/541 ,  A61K31/553 ,  C07D213/71 ,  C07D213/74 ,  C07D401/12 ,  C07D401/14 ,  C07D405/14 ,  C07D413/04 ,  C07D471/10 ,  C07D491/107 ,  C07D498/08 ,  C07D519/00

CPC classification number: C07D413/14 ,  A61K31/4439 ,  A61K31/444 ,  A61K31/4545 ,  A61K31/5377 ,  A61K31/5386 ,  A61K31/541 ,  A61K31/553 ,  C07D213/71 ,  C07D213/74 ,  C07D401/12 ,  C07D401/14 ,  C07D405/14 ,  C07D413/04 ,  C07D471/10 ,  C07D491/107 ,  C07D498/08 ,  C07D519/00

Abstract: The present invention relates to new pyridine-sulfonamide derivatives of formula (I′) as sigma ligands having a great affinity for sigma receptors, especially the sigma-1 receptor (σ1) and/or sigma-2 receptor (σ2), as well as to the process for the preparation thereof, to compositions comprising them, and to their use as medicaments.

公开(公告)号：US20240246991A1

公开(公告)日：2024-07-25

申请号：US18531320

申请日：2023-12-06

Applicant: Novartis AG

Inventor： Zhongbo Fei ,  Huanqing Jia ,  Wei Li ,  Xiaohui Lin ,  Zhongcheng Min ,  Hui Wang ,  Jianhua Wang ,  Hao Zhang

IPC: C07D491/107

CPC classification number: C07D491/107

Abstract: The present invention relates to a method for the manufacture of a compound of Formula I or a pharmaceutically acceptable salt, acid co-crystal, hydrate or other solvate thereof, said method comprising reacting a compound of the formula II with a compound of the formula III according to the following reaction scheme:




wherein LG, A, n, m and p are as defined in the Summary of the Invention.

公开(公告)号：US20240239774A1

公开(公告)日：2024-07-18

申请号：US18288368

申请日：2022-04-27

Applicant: Cornell University ,  Tri-Institutional Therapeutics Discovery Institue, Inc.

Inventor： Melanie Balbach ,  Jochen Buck ,  Lonny R. Levin ,  Jonathan Hale Zippin ,  Clemens Steegborn ,  Makoto Fushimi ,  David John Huggins ,  Nigel Liverton ,  Peter T. Meinke ,  Mayako Michino ,  Michael Miller

IPC: C07D409/14 ,  A61K31/506 ,  A61K31/5377 ,  A61K31/5386 ,  A61P15/16 ,  A61P29/00 ,  C07D401/14 ,  C07D403/04 ,  C07D403/14 ,  C07D405/14 ,  C07D413/14 ,  C07D417/14 ,  C07D491/107 ,  C07D498/18

CPC classification number: C07D409/14 ,  A61K31/506 ,  A61K31/5377 ,  A61K31/5386 ,  A61P15/16 ,  A61P29/00 ,  C07D401/14 ,  C07D403/04 ,  C07D403/14 ,  C07D405/14 ,  C07D413/14 ,  C07D417/14 ,  C07D491/107 ,  C07D498/18

Abstract: Provided herein are soluble adenylyl cyclase (sAC) inhibitors and uses thereof. In one aspect, provided herein are compounds of Formula (I), and pharmaceutically acceptable salts, hydrates, solvates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, and prodrugs thereof, and pharmaceutical compositions thereof. The compounds provided herein are soluble adenylyl cyclase (sAC) inhibitors and are therefore useful for the treatment and/or prevention of various diseases and conditions (e.g., ocular conditions (e.g., ocular hypotony), liver diseases (e.g., non-alcoholic steatohepatitis (NASH)), inflammatory diseases, autoimmune diseases (e.g., psoriasis)). Compounds provided herein are also useful as contraceptive agents (e.g., for male and female contraception).

公开(公告)号：US20240226114A1

公开(公告)日：2024-07-11

申请号：US18477240

申请日：2023-09-28

Applicant: Vividion Therapeutics, Inc.

Inventor： David WEINSTEIN ,  Jason GREEN ,  Shota KIKUCHI ,  Donald C ROGNESS ,  Philip ALIBI ,  Matthew PATRICELLI ,  Nilotpal ROY ,  I-Chung LO

IPC: A61K31/553 ,  A61K31/496 ,  A61K31/506 ,  A61K31/53 ,  A61K31/5377 ,  A61K31/5386 ,  A61K31/541 ,  A61P35/00 ,  C07D241/04 ,  C07D265/30 ,  C07D265/34 ,  C07D401/10 ,  C07D401/14 ,  C07D403/10 ,  C07D405/10 ,  C07D413/10 ,  C07D413/14 ,  C07D417/10 ,  C07D471/04 ,  C07D487/04 ,  C07D491/107 ,  C07D498/10

CPC classification number: A61K31/553 ,  A61K31/496 ,  A61K31/506 ,  A61K31/53 ,  A61K31/5377 ,  A61K31/5386 ,  A61K31/541 ,  A61P35/00 ,  C07D241/04 ,  C07D265/30 ,  C07D265/34 ,  C07D401/10 ,  C07D401/14 ,  C07D403/10 ,  C07D405/10 ,  C07D413/10 ,  C07D413/14 ,  C07D417/10 ,  C07D471/04 ,  C07D487/04 ,  C07D491/107 ,  C07D498/10

Abstract: Compounds and methods for inhibiting Nrf2 by activating KEAP1.

公开(公告)号：US20240208993A1

公开(公告)日：2024-06-27

申请号：US18544546

申请日：2023-12-19

Applicant: HANGZHOU POLYMED BIOPHARMACEUTICALS, INC.

Inventor： Jason Shaoyun XIANG ,  Lei WU ,  Rui XU ,  Qiang ZHANG ,  Gang YANG ,  Michael XIANG ,  Mixue TONG ,  Camille XIANG ,  Yuxin LIU ,  Suyue WANG ,  Rui YANG

IPC: C07D498/08 ,  A61K31/422 ,  A61K31/437 ,  A61K31/439 ,  A61K31/4439 ,  A61K31/4545 ,  A61K31/496 ,  A61K31/4985 ,  A61K31/5377 ,  A61K31/5386 ,  A61P35/02 ,  C07D401/14 ,  C07D413/14 ,  C07D417/14 ,  C07D471/04 ,  C07D471/08 ,  C07D487/04 ,  C07D491/107 ,  C07D493/08 ,  C07D498/04 ,  C07D513/04 ,  C07D519/00

CPC classification number: C07D498/08 ,  A61K31/422 ,  A61K31/437 ,  A61K31/439 ,  A61K31/4439 ,  A61K31/4545 ,  A61K31/496 ,  A61K31/4985 ,  A61K31/5377 ,  A61K31/5386 ,  A61P35/02 ,  C07D401/14 ,  C07D413/14 ,  C07D417/14 ,  C07D471/04 ,  C07D471/08 ,  C07D487/04 ,  C07D491/107 ,  C07D493/08 ,  C07D498/04 ,  C07D513/04 ,  C07D519/00

Abstract: A five-membered-fused six-membered compound, and a preparation method therefor and a pharmaceutical composition and the use thereof. The five- and six-membered compound is a compound as shown in formula I, II or III. The compound has an inhibitory effect on FLT3 and/or IRAK4.

公开(公告)号：US20240208945A1

公开(公告)日：2024-06-27

申请号：US18550468

申请日：2022-03-24

Applicant: MEDSHINE DISCOVERY INC.

Inventor： Lingyun WU ,  Tianzi DAI ,  Lele ZHAO ,  Jianjun SUN ,  Yi QIAN ,  Jian LI ,  Shuhui CHEN

IPC: C07D403/12 ,  A61K31/517 ,  A61K31/519 ,  A61K31/5377 ,  A61K31/551 ,  A61P35/00 ,  C07D401/12 ,  C07D405/14 ,  C07D413/12 ,  C07D471/04 ,  C07D487/04 ,  C07D487/08 ,  C07D491/048 ,  C07D491/107

CPC classification number: C07D403/12 ,  A61K31/517 ,  A61K31/519 ,  A61K31/5377 ,  A61K31/551 ,  A61P35/00 ,  C07D401/12 ,  C07D405/14 ,  C07D413/12 ,  C07D471/04 ,  C07D487/04 ,  C07D487/08 ,  C07D491/048 ,  C07D491/107

Abstract: Disclosed are 6-carbamate substituted heteroaryl ring derivatives and a preparation method therefor. The present application particularly relates to a compound as shown in formula (II) and a pharmaceutically acceptable salt thereof.

公开(公告)号：US20240174665A1

公开(公告)日：2024-05-30

申请号：US18453163

申请日：2023-08-21

Applicant: Kymera Therapeutics, Inc.

Inventor： Philip COLLIER ,  Xiaozhang ZHENG ,  Xiao ZHU ,  Melissa FORD ,  Matthew M. WEISS ,  Robert AVERSA ,  Kiran Vijayakumari MAHASENAN ,  Yi ZHANG

IPC: C07D471/04 ,  C07D215/227 ,  C07D231/40 ,  C07D239/42 ,  C07D239/84 ,  C07D401/04 ,  C07D401/12 ,  C07D401/14 ,  C07D403/04 ,  C07D403/12 ,  C07D403/14 ,  C07D405/14 ,  C07D413/12 ,  C07D473/18 ,  C07D487/04 ,  C07D491/107 ,  C07D491/20 ,  C07D495/04 ,  C07D513/04 ,  C07D519/00

CPC classification number: C07D471/04 ,  C07D215/227 ,  C07D231/40 ,  C07D239/42 ,  C07D239/84 ,  C07D401/04 ,  C07D401/12 ,  C07D401/14 ,  C07D403/04 ,  C07D403/12 ,  C07D403/14 ,  C07D405/14 ,  C07D413/12 ,  C07D473/18 ,  C07D487/04 ,  C07D491/107 ,  C07D491/20 ,  C07D495/04 ,  C07D513/04 ,  C07D519/00 ,  C07B2200/05

Abstract: The present invention provides compounds, compositions thereof, and methods of using the same.